Current Studies
Please get in touch with our Research department for further information regarding participating in a clinical trial. Lake Cumberland Rheumatology’s Research department can be reached by email at [email protected] or by phone by dialing (502) 351-6983.
The LC Rheumatology staff that are a part of the research team include:
Coordinators: Lisa Boone, RN, BSN, CCRC, Research Manager and Kara Lay
Primary Investigators: Scott Lewis, DO and Tmothy Lonesky, DO
Sub-Investigators: Natalie Lane, APRN, Dana Mann, APRN, and Charles Moore, MD
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Clinical Trial to Evaluate the Long-Term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Sponsor: AMGEN
Participants must be:
- 18 years of age or older, newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis
- starting treatment with cyclophosphamide or rituximab
A Randomized, Double-Blind, Parallel Group Placebo[1] Controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety, and Tolerability of Two Regiments of Ianalumab on Top of Standard-Of-Care Therapy with Patients with Systematic Lupus Erythematosus (SIRIUS-SLE 1)
Sponsor: NOVARTIS
Participants must be:
-
18 years of age or older, diagnosed with Systemic Lupus Erythematosus for at least 6 months before screening
-
having symptoms or flare on current oral anti-malarial/DMARD/corticosteroid therapy, and ready to start a biologic medication
A Study to Investigate Effectiveness of Tirzepatide in Clinical Practice following Initiation of Ixekizumab in Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Sponsor: ELI LILLY
Participants must be:
- 18 years or older, diagnosed with Psoriatic Arthritis.
- BMI of 30 and treated with Taltz for 3 months, able to start Zepbound (cannot have any prior exposure to Zepbound/Mounjaro/Wegovy/Trulicity/Victoza)
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (PHOENYCS FLY)
Sponsor: UCB
Participants must be:
-
18 years of age or older, diagnosed with Systemic Lupus Erythematosus for at least 6 months
-
having symptoms or flare on current oral anti-malarial/DMARD/corticosteroid therapy, and ready to start a biologic medication
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease (UNITY)
Sponsor: ARGENX
Participants must be:
-
18 years or older, Diagnosed with primary Sjogren’s disease
-
currently not on medication or currently on oral medication ready to start a biologic, positive Sjogren’s antibody lab test (anti-Ro/SS-A)
A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Researcher-directed Biomedical Research Initiatives
Sponsor: SANGUINE Biosciences
Participants must be:
-
18 years or older, diagnosed Moderate to Severe Rheumatoid Arthritis, or Ankylosing Spondylitis
-
willing to provide knee synovial fluid and blood samples
Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry (SLE-800) and Biorepository (BIO-800)
Sponsor: CorEvitas
Participants must be:
-
18 years or older, diagnosed Systemic Lupus Erythematosus
-
currently a LCR patient, willing to provide blood samples
